Department of Oncology, Jinan Central Hospital, Affiliated to Shandong University, No, 105,Jiefang Road, Jinan, Shandong 250013, P,R, China.
Diagn Pathol. 2014 Jun 27;9:128. doi: 10.1186/1746-1596-9-128.
Metastatic spread of tumor through lymphatic vasculature is an important adverse prognostic factor in a variety of human cancer and tumor lymphangiogenesis requires the interplay of several growth factors. Platelet-derived growth factor (PDGF)-BB and vascular endothelial growth factor (VEGF)-C are two important molecules involving in tumor metastasis and lymphangiogenesis. Therefore, the aim of this study was to investigate the coexpression of PDGF-BB and VEGF-C in primary human non-small cell lung cancer (NSCLC) and its association with lymphangiogenesis.
Using immunohistochemical staining, PDGF-BB and VEGF-C expression were detected in 109 primary NSCLC tissues, while the lymphatic micro-vessel density (LMVD) was counted.
Of 109 cases, PDGF-BB and VEGF-C overexpression was 66.97% (73/109) and 65.14% (71/109), respectively. 52 (47.7%) had overexpression of both PDGF-BB and VEGF-C (P+V+), 21 (19.3%) overexpression of PDGF-BB but low expression of VEGF-C (P+V-), 19(17.4%) overexpression of VEGF-C but low expression of PDGF-BB (P-V+) and 17(15.6%) low expression of both PDGF-BB and VEGF-C (P-V-). PDGF-BB expression was positively related to that of VEGF-C (r=0.451, p=0.034). LMVD in cases with P+V+was much higher than those with P-V- (p=0.004). In addition, the patients with P+V+were younger and also had larger tumor size, more likely lymph node metastasis and worse histological differentiation than those with P-V-. Moreover, the overall survival (OS) of patients with P+V+was shorter than those with P-V- (p=0.015).
Coexpression of both PDGF-BB and VEGF-C was associated with lymphangiogenesis and poor prognosis in NSCLC, and might play a critical role in NSCLC progression.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2261801312571320.
肿瘤通过淋巴血管系统转移是多种人类癌症的重要不良预后因素,肿瘤淋巴管生成需要几种生长因子的相互作用。血小板衍生生长因子(PDGF)-BB 和血管内皮生长因子(VEGF)-C 是两种参与肿瘤转移和淋巴管生成的重要分子。因此,本研究旨在探讨 PDGF-BB 和 VEGF-C 在原发性非小细胞肺癌(NSCLC)中的共表达及其与淋巴管生成的关系。
采用免疫组织化学染色法检测 109 例原发性 NSCLC 组织中 PDGF-BB 和 VEGF-C 的表达情况,并计数淋巴管密度(LMVD)。
在 109 例病例中,PDGF-BB 和 VEGF-C 的过表达率分别为 66.97%(73/109)和 65.14%(71/109)。52 例(47.7%)同时过表达 PDGF-BB 和 VEGF-C(P+V+),21 例(19.3%)过表达 PDGF-BB 但低表达 VEGF-C(P+V-),19 例(17.4%)过表达 VEGF-C 但低表达 PDGF-BB(P-V+),17 例(15.6%)同时低表达 PDGF-BB 和 VEGF-C(P-V-)。PDGF-BB 表达与 VEGF-C 表达呈正相关(r=0.451,p=0.034)。P+V+病例的 LMVD 明显高于 P-V-病例(p=0.004)。此外,P+V+患者较 P-V-患者年龄更小,肿瘤体积更大,更易发生淋巴结转移,组织学分化程度更低。而且,P+V+患者的总生存期(OS)明显短于 P-V-患者(p=0.015)。
PDGF-BB 和 VEGF-C 的共表达与 NSCLC 的淋巴管生成和不良预后相关,可能在 NSCLC 的进展中发挥关键作用。